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Background:  To evaluate prevalence of in-hospital use of potentially harmful drugs (PHD) in heart failure (HF) patients and analyze their 
impact on length of stay and in-hospital mortality.
methods:  The University HealthSystem Consortium Database was queried for admissions with the primary diagnosis of HF during 2011-
2014 based on applicable DRG codes and harmful drugs names (see Table 1 for details). Patients were divided into three groups systolic 
heart failure (SHF), Diastolic heart failure (DHF) and not otherwise specified heart failure (NOSHF).
results:  A retrospective analysis of 220,642 admissions for primary HF was conducted. Exposure to PHD was observed in 16,802 
(13.4%) SHF; 29,664 (15.5%) NOS HF and 5,141 (8.5%) in DHF cases. In-hospital mortality was significantly higher in SHF patients 
exposed to PHD compared to no exposure (3.73% vs. 3.26%, p =0.003). No difference in mortality was observed with exposure to PHD in 
NOS HF and DHF (3.34% vs 3.54%, p=0.46; and 2.37% vs 2.48%, p=0.63) respectively. Length of stay was significantly prolonged when 
exposed to PHD: 11.41± 1.57 vs 7.19±0.24 days for SHF; 7.01±0.41 vs 4.79±0.13 days for NOS HF and 7.15±0.49 vs 5.83 ± 0.11 days in 
DHF.
conclusion:  In-hospital exposure to PHD is not uncommon and was associated with increased in-hospital mortality in SHF and significant 
longer lengths of stay in SHF, DHF and NOSHF.
Table 1. Classification and definitions of Heart Failure and Potentially Harmful Drugs
Heart Failure Classification (DRG)
Systolic heart failure (SHF) 428.2; 428.20; 428.21; 428.22; 428.23; 428.4; 428.40; 428.41; 428.42; 428.43
Not otherwise specified heart failure (NOS 
HF) 428.0; 428.1; 428.9
Diastolic heart failure (DHF) 428.3; 428.30; 428.31; 428.32; 428.33
Potentially Harmful Drugs Classification* (monotherapy and combination products)
Alpha 1 blockers doxazosin, prazosin, terazosin
Anti-arrhythmic dronedarone, flecainide, procainamide, propafenone, quinidine, dysopiramide, ibutilide
Non-steroidal anti-inflammatory agents 
(NSAIDS)
celecoxib, diclofenac, etodolac, flurbiprofen (systemic), ibuprofen, indomethacin, 
ketoprofen, ketorolac, meclofenamate, meloxicam, nabumetone, naproxen, piroxicam, 
sulindac, tolmetin
Non-dihydropyridine calcium channel 
blockers (NDHP CCB) diltiazem, verapamil
Thiazolidinedione (TZD) pioglitazone, rosiglitazone
* SHF and NOS HF utilized all 5 categories and DHF used NSAIDS, TZD, and Alpha 1 blockers for PHD
